1. Generics Bulletin
  3. >>Generics

Supreme Court Denies Norwich Bid For US Xifaxan Reprieve

Refuses Request For Certiorari Over Skinny-Label Rifaximin Generic

 
• By Dave Wallace

The US Supreme Court has failed to come to the aid of Norwich Pharmaceuticals in its legal battle over a generic version of Xifaxan (rifaximin) that has a patented indication carved out of its label. An earlier decision over the generic thus bars approval and launch until 2029.

The Supreme Court denied Norwich’s request to review the case (Shutterstock)

Norwich Pharmaceuticals has seen denied its petition for the US Supreme Court to review litigation that has blocked its generic version of Bausch Health’s Xifaxan (rifaximin) from being approved by the US Food and Drug Administration until 2029, even though it has now carved out a patent-protected indication from the generic’s label.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Generics

More from Generics Bulletin